RecruitingNot ApplicableNCT05967273

CirrhosisRx CDS System

Pragmatic Randomized Controlled Trial to Evaluate the Effect of CirrhosisRx, a Novel Clinical Decision Support System, on Guideline-adherence and Clinical Outcomes for Patients With Cirrhosis


Sponsor

University of California, San Francisco

Enrollment

2,106 participants

Start Date

Jan 14, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

The aim of the study is to compare the effect of CirrhosisRx, a novel clinical decision support (CDS) system for inpatient cirrhosis care, versus "usual care" on adherence to national quality measures and clinical outcomes for hospitalized patients with cirrhosis.


Eligibility

Min Age: 18 Years

Inclusion Criteria1

  • All adult (age ≥ 18 years) patients who have cirrhosis identified based on 1+ chronic liver disease and 1+ cirrhosis (or its complications) International Classification of Diseases, Revision 10 diagnosis codes OR mention of cirrhosis or portal hypertension (or their complications) in clinical documentation admitted at our institution.

Exclusion Criteria3

  • Children (age \< 18 years)
  • patients who do not meet the cirrhosis definition criteria as noted above
  • ambulatory patients

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERCirrhosisRx CDS

CirrhosisRx is a cirrhosis-specific CDS that organizes clinical data into clinically relevant groupings and links them to order sets consistent with national practice guidelines for inpatient cirrhosis care.


Locations(1)

University of California San Francisco Medical Center

San Francisco, California, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05967273


Related Trials